Algorae Pharmaceuticals Ltd - Asset Resilience Ratio
Algorae Pharmaceuticals Ltd (1AI) has an Asset Resilience Ratio of 37.48% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Algorae Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Check Algorae Pharmaceuticals Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Algorae Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 1AI market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$750.00K | 37.48% |
| Total Liquid Assets | AU$750.00K | 37.48% |
Asset Resilience Insights
- Very High Liquidity: Algorae Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 37.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Algorae Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Algorae Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
Annual Asset Resilience Ratio for Algorae Pharmaceuticals Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Algorae Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 77.13% | AU$1.85 Million ≈ $1.31 Million |
AU$2.40 Million ≈ $1.70 Million |
+35.26pp |
| 2024-06-30 | 41.87% | AU$2.30 Million ≈ $1.63 Million |
AU$5.49 Million ≈ $3.89 Million |
-- |
| 2023-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$6.23 Million ≈ $4.41 Million |
-- |
| 2022-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$4.27 Million ≈ $3.02 Million |
-- |
| 2021-06-30 | 2.64% | AU$43.30K ≈ $30.64K |
AU$1.64 Million ≈ $1.16 Million |
-86.07pp |
| 2020-06-30 | 88.71% | AU$3.01 Million ≈ $2.13 Million |
AU$3.39 Million ≈ $2.40 Million |
+3.50pp |
| 2019-06-30 | 85.21% | AU$4.91 Million ≈ $3.47 Million |
AU$5.76 Million ≈ $4.08 Million |
-4.97pp |
| 2018-06-30 | 90.18% | AU$6.86 Million ≈ $4.86 Million |
AU$7.61 Million ≈ $5.38 Million |
+3.57pp |
| 2017-06-30 | 86.61% | AU$7.53 Million ≈ $5.33 Million |
AU$8.69 Million ≈ $6.15 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$6.31 Million ≈ $4.47 Million |
-- |
About Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more